150 related articles for article (PubMed ID: 24593055)
1. Beta-blocker usage after malignant melanoma diagnosis and survival: a population-based nested case-control study.
McCourt C; Coleman HG; Murray LJ; Cantwell MM; Dolan O; Powe DG; Cardwell CR
Br J Dermatol; 2014 Apr; 170(4):930-8. PubMed ID: 24593055
[TBL] [Abstract][Full Text] [Related]
2. β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
Hicks BM; Murray LJ; Powe DG; Hughes CM; Cardwell CR
Ann Oncol; 2013 Dec; 24(12):3100-6. PubMed ID: 24050955
[TBL] [Abstract][Full Text] [Related]
3. Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort.
Cardwell CR; Coleman HG; Murray LJ; Entschladen F; Powe DG
Int J Epidemiol; 2013 Dec; 42(6):1852-61. PubMed ID: 24536096
[TBL] [Abstract][Full Text] [Related]
4. Beta-blocker usage and prostate cancer survival: a nested case-control study in the UK Clinical Practice Research Datalink cohort.
Cardwell CR; Coleman HG; Murray LJ; O'Sullivan JM; Powe DG
Cancer Epidemiol; 2014 Jun; 38(3):279-85. PubMed ID: 24786858
[TBL] [Abstract][Full Text] [Related]
5. Does Angiotensin-Converting Enzyme Inhibitor and β-Blocker Use Reduce the Risk of Primary Liver Cancer? A Case-Control Study Using the U.K. Clinical Practice Research Datalink.
Hagberg KW; Sahasrabuddhe VV; McGlynn KA; Jick SS
Pharmacotherapy; 2016 Feb; 36(2):187-95. PubMed ID: 26846893
[TBL] [Abstract][Full Text] [Related]
6. β-Blockers and survival among Danish patients with malignant melanoma: a population-based cohort study.
Lemeshow S; Sørensen HT; Phillips G; Yang EV; Antonsen S; Riis AH; Lesinski GB; Jackson R; Glaser R
Cancer Epidemiol Biomarkers Prev; 2011 Oct; 20(10):2273-9. PubMed ID: 21933972
[TBL] [Abstract][Full Text] [Related]
7. β-Blocker use and all-cause mortality of melanoma patients: results from a population-based Dutch cohort study.
Livingstone E; Hollestein LM; van Herk-Sukel MP; van de Poll-Franse L; Nijsten T; Schadendorf D; de Vries E
Eur J Cancer; 2013 Dec; 49(18):3863-71. PubMed ID: 23942335
[TBL] [Abstract][Full Text] [Related]
8. β-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
De Giorgi V; Grazzini M; Benemei S; Marchionni N; Geppetti P; Gandini S
Melanoma Res; 2017 Jun; 27(3):268-270. PubMed ID: 28346289
[TBL] [Abstract][Full Text] [Related]
9. Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.
Couttenier A; Lacroix O; Silversmit G; Vaes E; De Schutter H; Robert A
Cancer Epidemiol; 2019 Oct; 62():101579. PubMed ID: 31450179
[TBL] [Abstract][Full Text] [Related]
10. Use of beta-blockers and the risk of hip/femur fracture in the United Kingdom and The Netherlands.
de Vries F; Souverein PC; Cooper C; Leufkens HG; van Staa TP
Calcif Tissue Int; 2007 Feb; 80(2):69-75. PubMed ID: 17308987
[TBL] [Abstract][Full Text] [Related]
11. Association between beta-blockers, other antihypertensive drugs and psoriasis: population-based case-control study.
Brauchli YB; Jick SS; Curtin F; Meier CR
Br J Dermatol; 2008 Jun; 158(6):1299-307. PubMed ID: 18410416
[TBL] [Abstract][Full Text] [Related]
12. National use and effectiveness of beta-blockers for the treatment of elderly patients after acute myocardial infarction: National Cooperative Cardiovascular Project.
Krumholz HM; Radford MJ; Wang Y; Chen J; Heiat A; Marciniak TA
JAMA; 1998 Aug; 280(7):623-9. PubMed ID: 9718054
[TBL] [Abstract][Full Text] [Related]
13. Effect of β-blockers and other antihypertensive drugs on the risk of melanoma recurrence and death.
De Giorgi V; Gandini S; Grazzini M; Benemei S; Marchionni N; Geppetti P
Mayo Clin Proc; 2013 Nov; 88(11):1196-203. PubMed ID: 24182700
[TBL] [Abstract][Full Text] [Related]
14. Assessing the effects of beta-blockers on pancreatic cancer risk: A nested case-control study.
Saad A; Goldstein J; Margalit O; Shacham-Shmueli E; Lawrence YR; Yang YX; Reiss KA; Golan T; Mamtani R; Halpern N; Aderka D; Mouallem M; Goldstein A; Giantonio B; Boursi B
Pharmacoepidemiol Drug Saf; 2020 May; 29(5):599-604. PubMed ID: 32196836
[TBL] [Abstract][Full Text] [Related]
15. Treatment with β-blockers and reduced disease progression in patients with thick melanoma.
De Giorgi V; Grazzini M; Gandini S; Benemei S; Lotti T; Marchionni N; Geppetti P
Arch Intern Med; 2011 Apr; 171(8):779-81. PubMed ID: 21518948
[TBL] [Abstract][Full Text] [Related]
16. Beta-Blocker Use and Lung Cancer Mortality in a Nationwide Cohort Study of Patients with Primary Non-Small Cell Lung Cancer.
Udumyan R; Montgomery S; Fang F; Valdimarsdottir U; Hardardottir H; Ekbom A; Smedby KE; Fall K
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):119-126. PubMed ID: 31641010
[TBL] [Abstract][Full Text] [Related]
17. Stage-specific associations between beta blocker use and prognosis after colorectal cancer.
Jansen L; Hoffmeister M; Arndt V; Chang-Claude J; Brenner H
Cancer; 2014 Apr; 120(8):1178-86. PubMed ID: 24415516
[TBL] [Abstract][Full Text] [Related]
18. Postdiagnostic Calcium Channel Blocker Use and Breast Cancer Mortality: A Population-based Cohort Study.
Busby J; Mills K; Zhang SD; Liberante FG; Cardwell CR
Epidemiology; 2018 May; 29(3):407-413. PubMed ID: 29608546
[TBL] [Abstract][Full Text] [Related]
19. Hypotensive medication, statins, and the risk of glaucoma.
Owen CG; Carey IM; Shah S; de Wilde S; Wormald R; Whincup PH; Cook DG
Invest Ophthalmol Vis Sci; 2010 Jul; 51(7):3524-30. PubMed ID: 20130286
[TBL] [Abstract][Full Text] [Related]
20. Beta blocker use and colorectal cancer risk: population-based case-control study.
Jansen L; Below J; Chang-Claude J; Brenner H; Hoffmeister M
Cancer; 2012 Aug; 118(16):3911-9. PubMed ID: 22585669
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
